Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 25

PMID 35326741

Authors

Jinfang Liu

Jun Xu

Binlin Luo

Jian Tang

Zuoqiong Hou

Zhechen Zhu

Lingjun Zhu

Gang Yao

Chujun Li

Affiliations

Soon will be listed here.

Abstract

Background: Current studies have revealed that RNA-binding protein RBM38 is closely related to tumor development, while its role in malignant melanoma remains unclear. Therefore, this research aimed to investigate the function of RBM38 in melanoma and the prognosis of the disease.

Methods: Functional experiments (CCK-8 assay, cell colony formation, transwell cell migration/invasion experiment, wound healing assay, nude mouse tumor formation, and immunohistochemical analysis) were applied to evaluate the role of RBM38 in malignant melanoma. Immune-associated differentially expressed genes (DEGs) on RBM38 related immune pathways were comprehensively analyzed based on RNA sequencing results.

Results: We found that high expression of RBM38 promoted melanoma cell proliferation, invasion, and migration, and RBM38 was associated with immune infiltration. Then, a five-gene (A2M, NAMPT, LIF, EBI3, and ERAP1) model of RBM38-associated immune DEGs was constructed and validated. Our signature showed superior prognosis capacity compared with other melanoma prognostic signatures. Moreover, the risk score of our signature was connected with the infiltration of immune cells, immune-regulatory proteins, and immunophenoscore in melanoma.

Conclusions: We constructed an immune prognosis model using RBM38-related immune DEGs that may help evaluate melanoma patient prognosis and immunotherapy modalities.

Citing Articles

Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups.

Grutzmann K, Kraft T, Meinhardt M, Meier F, Westphal D, Seifert M Comput Struct Biotechnol J. 2024; 23:1036-1050.

PMID: 38464935 PMC: 10920107. DOI: 10.1016/j.csbj.2024.02.013.

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma.

Hu Z, Sun W, Wen Y, Ma R, Chen L, Chen W Front Immunol. 2022; 13:952059.

PMID: 36045683 PMC: 9421049. DOI: 10.3389/fimmu.2022.952059.

References

Givechian K, Wnuk K, Garner C, Benz S, Garban H, Rabizadeh S . Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. NPJ Genom Med. 2018; 3:14. PMC: 5998068. DOI: 10.1038/s41525-018-0054-7. View

Shu L, Yan W, Chen X . RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev. 2006; 20(21):2961-72. PMC: 1620019. DOI: 10.1101/gad.1463306. View

Meyer S, Fuchs T, Bosserhoff A, Hofstadter F, Pauer A, Roth V . A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One. 2012; 7(6):e38222. PMC: 3369875. DOI: 10.1371/journal.pone.0038222. View

Hui L, Chen Y . Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 2015; 368(1):7-13. DOI: 10.1016/j.canlet.2015.07.039. View

Liu N, Liu Z, Liu X, Duan X, Huang Y, Jin Z . Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in Melanoma. Front Genet. 2020; 11:1002. PMC: 7484056. DOI: 10.3389/fgene.2020.01002. View

Castello A, Fischer B, Hentze M, Preiss T . RNA-binding proteins in Mendelian disease. Trends Genet. 2013; 29(5):318-27. DOI: 10.1016/j.tig.2013.01.004. View

Saranga-Perry V, Ambe C, Zager J, Kudchadkar R . Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014; 64(3):171-85. DOI: 10.3322/caac.21224. View

van Houdt I, Sluijter B, Moesbergen L, Vos W, de Gruijl T, Molenkamp B . Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer. 2008; 123(3):609-15. DOI: 10.1002/ijc.23543. View

Cho S, Jung Y, Zhang J, Chen X . The RNA-binding protein RNPC1 stabilizes the mRNA encoding the RNA-binding protein HuR and cooperates with HuR to suppress cell proliferation. J Biol Chem. 2012; 287(18):14535-44. PMC: 3340227. DOI: 10.1074/jbc.M111.326827. View

10.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

11.

Xue J, Xia T, Liang X, Zhou W, Cheng L, Shi L . RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer. BMC Cancer. 2014; 14:322. PMC: 4101826. DOI: 10.1186/1471-2407-14-322. View

12.

Avula L, Knapen D, Buckinx R, Vergauwen L, Adriaensen D, van Nassauw L . Whole-genome microarray analysis and functional characterization reveal distinct gene expression profiles and patterns in two mouse models of ileal inflammation. BMC Genomics. 2012; 13:377. PMC: 3599598. DOI: 10.1186/1471-2164-13-377. View

13.

Luo H, Ma C, Shao J, Cao J . Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma. Front Oncol. 2020; 10:567512. PMC: 7661968. DOI: 10.3389/fonc.2020.567512. View

14.

Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L . A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol. 2012; 139(2):249-58. DOI: 10.1007/s00432-012-1322-z. View

15.

Nsengimana J, Laye J, Filia A, OShea S, Muralidhar S, Pozniak J . β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J Clin Invest. 2018; 128(5):2048-2063. PMC: 5919828. DOI: 10.1172/JCI95351. View

16.

Bar-Shira A, Pinthus J, Rozovsky U, Goldstein M, Sellers W, Yaron Y . Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002; 62(23):6803-7. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Zheng S, Xu J, ISAACS S, Wiley K, Chang B, Bleecker E . Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet. 2001; 108(5):430-5. DOI: 10.1007/s004390100513. View

19.

Bakhshi T, Georgel P . Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J. 2020; 10(12):123. PMC: 7718920. DOI: 10.1038/s41408-020-00389-w. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View